Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.41 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.41 |
| ▸ | CHRNA3 | P32297 | 4/20 | 0.40 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | LTA4H | P09960 | 6/20 | 0.38 |
| ▸ | HTR6 | P50406 | 3/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6338391 | 0.99 | CHRNB2 (0.41) | CHRNB2CHRNA4CHRNA3CHRNB4SLC6A2 | |
| SCHEMBL6339018 | 0.97 | CHRNB2 (0.44) | CHRNB2CHRNA4CHRNA3CHRNB4SLC6A2 | |
| SCHEMBL6339079 | 0.89 | CHRNB2 (0.41) | CHRNB2CHRNA4CHRNA3CHRNB4SLC6A2 | |
| SCHEMBL6338654 | 0.88 | CHRNB2 (0.41) | CHRNB2CHRNA4CHRNA3CHRNB4SLC6A2 | |
| SCHEMBL6338663 | 0.86 | CHRNB2 (0.44) | CHRNB2CHRNA4CHRNA3CHRNB4SLC6A2 | |
| SCHEMBL6342667 | 0.84 | HTR6 (0.49) | CHRNB2CHRNA4CHRNA3CHRNB4LTA4H | |
| SCHEMBL6347984 | 0.84 | HTR6 (0.50) | CHRNB2CHRNA4CHRNA3CHRNB4HTR6 | |
| SCHEMBL6348652 | 0.83 | HTR6 (0.48) | CHRNB2CHRNA4CHRNA3CHRNB4LTA4H | |
| SCHEMBL6339816 | 0.82 | CHRNB2 (0.49) | CHRNB2CHRNA4CHRNA3CHRNB4HTR6 | |
| SCHEMBL6348882 | 0.81 | HTR6 (0.51) | CHRNB2CHRNA4CHRNA3CHRNB4SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050065185-A1 | Heterocyclylalkoxy-, -alkylthio- and -alkylaminobenzazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2005-03-24 | — | — | US | claimed |
| US-20030078286-A1 | Heterocyclylalkoxy-,-alkylthio-and -alkylaminobenzazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH | 2003-04-24 | — | — | US | claimed |
| US-20050065185-A1 | Heterocyclylalkoxy-, -alkylthio- and -alkylaminobenzazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2005-03-24 | — | — | US | disclosed |
| US-6831094-B2 | For therapy of central nervous system disorders such as anxiety, depression, motor disorders | WYETH | 2004-12-14 | — | — | US | disclosed |
| US-20030078286-A1 | Heterocyclylalkoxy-,-alkylthio-and -alkylaminobenzazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH | 2003-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050065185-A1 | Heterocyclylalkoxy-, -alkylthio- and -alkylaminobenzazole derivatives as 5-hydroxytryptamine-6 ligands | HTR6, HTR3B, HTR5A | CHRNB2 191/4885CHRNA4 184/4885CHRNA3 151/4885 |
| US-20030078286-A1 | Heterocyclylalkoxy-,-alkylthio-and -alkylaminobenzazole derivatives as 5-hydroxytryptamine-6 ligands | HTR6, HTR3B, HTR5A | CHRNB2 197/4885CHRNA4 192/4885CHRNA3 155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.